Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
AXL inhibitor | Small molecule | Oncology/Cancer | STK11_mut NSCLC,other cancers | Phase I | Global |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
AXL-H82F9 | Human | Biotinylated Human AXL Protein, Fc,Avitag™ (MALS verified) |
|
|
|
AXL-H5253 | Human | Human Axl Protein, Fc Tag (MALS verified) |
|
|
|
AXL-C52H3 | Cynomolgus | Cynomolgus Axl Protein, His Tag |
|
||
AXL-H5226 | Human | Human Axl Protein, His Tag (SPR verified) |
|
|
Human Axl, Fc Tag (Cat. No. AXL-H5253) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human GAS6, His Tag (Cat. No. GA6-H5249) with an affinity constant of 1.23 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Urethral Neoplasms; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Peritoneal Neoplasms; Bile Duct Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Adenocarcinoma, Clear Cell; Sarcoma, Ewing; Carcinoma, Adenosquamous; Breast Neoplasms; Neurofibroma, Plexiform; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Medullary thyroid cancer (MTC); Carcinoma, Hepatocellular; Melanoma; Paraganglioma; Meningioma; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Brain Neoplasms; Carcinoma, Neuroendocrine; Sarcoma, Alveolar Soft Part; Lymphoma; Fallopian Tube Neoplasms; Brain metastases; Glioma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoid Tumor; Glioblastoma; Skin Neoplasms; Neoplasms; Carcinoma, Papillary; Hepatoblastoma; Pheochromocytoma; Pain; Rejection of liver transplantation; Carcinoma, Renal Cell; Pancreatic neuroendocrine tumors | Details |
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Urethral Neoplasms; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Peritoneal Neoplasms; Bile Duct Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Adenocarcinoma, Clear Cell; Sarcoma, Ewing; Carcinoma, Adenosquamous; Breast Neoplasms; Neurofibroma, Plexiform; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Medullary thyroid cancer (MTC); Carcinoma, Hepatocellular; Melanoma; Paraganglioma; Meningioma; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Brain Neoplasms; Carcinoma, Neuroendocrine; Sarcoma, Alveolar Soft Part; Lymphoma; Fallopian Tube Neoplasms; Brain metastases; Glioma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoid Tumor; Glioblastoma; Skin Neoplasms; Neoplasms; Carcinoma, Papillary; Hepatoblastoma; Pheochromocytoma; Pain; Rejection of liver transplantation; Carcinoma, Renal Cell; Pancreatic neuroendocrine tumors | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
Sitravatinib | MG-91516; MGCD-516; IND-155305; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Mecbotamab vedotin | BA-3011; BA3011; BA 3011 | Phase 2 Clinical | Bioatla | Ovarian Neoplasms; Sarcoma, Synovial; Liposarcoma; Osteosarcoma; Sarcoma, Ewing; Sarcoma; Carcinoma, Non-Small-Cell Lung | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
ONO-7475 | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Bemcentinib | BGB-324; R-428 | Phase 2 Clinical | Rigel Pharmaceuticals Inc | Adenocarcinoma of Lung; Myelodysplastic Syndromes; Pancreatic Neoplasms; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Mesothelioma; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Enapotamab vedotin | AXL-107-MMAE | Phase 2 Clinical | Genmab A/S | Ovarian Neoplasms; Solid tumours; Neoplasms; Sarcoma; Thyroid Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
CCT301-38 | CCT301-38; CCT301-38 AXL | Phase 2 Clinical | F1 Oncology, Bioatla | Carcinoma, Renal Cell; Rhinitis, Allergic, Seasonal | Details |
XZB-0004 | XZB-0004; SLC-0211; SLC-391 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases | Details |
Butylidenephthalide | BDPH; HK-001; NSC-325307; LF-001 (Everfront Biotech) | Phase 2 Clinical | Everfront Biotech Co Ltd | Glioma; Amyotrophic Lateral Sclerosis | Details |
Q-702 | Q-702 | Phase 2 Clinical | Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
Dubermatinib | TP-0903 | Phase 1 Clinical | Sumitomo Dainippon | Ovarian Neoplasms; Solid tumours; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Mipasetamab uzoptirine | ADCT-601; BGB-601 | Phase 1 Clinical | Adc Therapeutics Sa | Solid tumours | Details |
NTQ-2494 | NTQ2494; NTQ-2494 | Phase 1 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
AB-801 | AB-801 | Phase 1 Clinical | Arcus Biosciences Inc | Neoplasms | Details |
FC-084-CSA | FC084CSA; FC-084-CSA | Phase 1 Clinical | FindCure Biosciences (ZhongShan) Co Ltd | Solid tumours | Details |
NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
PF-07265807 | PF-07265807 | Phase 1 Clinical | Pfizer Inc | Solid tumours; Neoplasm Metastasis | Details |
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms | Details |
cancer therapeutics (BerGenBio) | BGB-101; BGB-109; BGB-003; BGB-001 | Phase 1 Clinical | Bergenbio | Details | |
NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details | ||
Zanzalintinib | XL-092 | Phase 3 Clinical | Exelixis Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
Sitravatinib | MG-91516; MGCD-516; IND-155305; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Mouth Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Ureteral Neoplasms; Hepatic Insufficiency; Solid tumours; Liposarcoma; Uveal melanoma; Lung Diseases; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Kidney Neoplasms | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Mecbotamab vedotin | BA-3011; BA3011; BA 3011 | Phase 2 Clinical | Bioatla | Ovarian Neoplasms; Sarcoma, Synovial; Liposarcoma; Osteosarcoma; Sarcoma, Ewing; Sarcoma; Carcinoma, Non-Small-Cell Lung | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
ONO-7475 | ONO-7475 | Phase 2 Clinical | Ono Pharmaceutical Co Ltd | Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Bemcentinib | BGB-324; R-428 | Phase 2 Clinical | Rigel Pharmaceuticals Inc | Adenocarcinoma of Lung; Myelodysplastic Syndromes; Pancreatic Neoplasms; Inflammatory Breast Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Mesothelioma; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Enapotamab vedotin | AXL-107-MMAE | Phase 2 Clinical | Genmab A/S | Ovarian Neoplasms; Solid tumours; Neoplasms; Sarcoma; Thyroid Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
CCT301-38 | CCT301-38; CCT301-38 AXL | Phase 2 Clinical | F1 Oncology, Bioatla | Carcinoma, Renal Cell; Rhinitis, Allergic, Seasonal | Details |
XZB-0004 | XZB-0004; SLC-0211; SLC-391 | Phase 2 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases | Details |
Butylidenephthalide | BDPH; HK-001; NSC-325307; LF-001 (Everfront Biotech) | Phase 2 Clinical | Everfront Biotech Co Ltd | Glioma; Amyotrophic Lateral Sclerosis | Details |
Q-702 | Q-702 | Phase 2 Clinical | Vichem Chemie, Max Planck Institute of Biochemistry, Lead Discovery Center GmbH | Solid tumours; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details |
Dubermatinib | TP-0903 | Phase 1 Clinical | Sumitomo Dainippon | Ovarian Neoplasms; Solid tumours; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
INCB-081776 | INCB-81776; INCB-081776 | Phase 1 Clinical | Incyte Corp | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Mipasetamab uzoptirine | ADCT-601; BGB-601 | Phase 1 Clinical | Adc Therapeutics Sa | Solid tumours | Details |
NTQ-2494 | NTQ2494; NTQ-2494 | Phase 1 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
AB-801 | AB-801 | Phase 1 Clinical | Arcus Biosciences Inc | Neoplasms | Details |
FC-084-CSA | FC084CSA; FC-084-CSA | Phase 1 Clinical | FindCure Biosciences (ZhongShan) Co Ltd | Solid tumours | Details |
NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
PF-07265807 | PF-07265807 | Phase 1 Clinical | Pfizer Inc | Solid tumours; Neoplasm Metastasis | Details |
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd | Solid tumours; Liver Neoplasms; Stomach Neoplasms; Lung Neoplasms | Details |
cancer therapeutics (BerGenBio) | BGB-101; BGB-109; BGB-003; BGB-001 | Phase 1 Clinical | Bergenbio | Details | |
NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details |
This web search service is supported by Google Inc.